The Claim
Monoclonal antibody-based PCSK9 inhibitors lead to a compensatory increase in circulating PCSK9 levels, while inclisiran decreases both intracellular and extracellular PCSK9 concentrations, reflecting distinct biological feedback mechanisms between these two therapeutic classes.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
One type of cholesterol drug makes the body produce more of a protein called PCSK9, while another type actually reduces it — so they work in opposite ways even though they target the same thing.
See the scientific wording
Monoclonal antibody-based PCSK9 inhibitors cause a compensatory increase in circulating PCSK9 levels, whereas inclisiran reduces both intracellular and extracellular PCSK9 concentrations, indicating divergent biological feedback responses between the two drug classes.
What the research says
1 studyStudy: Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
The study shows that one type of PCSK9 drug (antibodies) causes the body to make more PCSK9, while the other (inclisiran) reduces it, which matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.